NASDAQ: PSTVPlus Therapeutics Inc Stock
$0.54+0.01 (+1.89%)
Updated Oct 31, 2025
PSTV Price
$0.54
Fair Value Price
N/A
Market Cap
$74.21M
52 Week Low
$0.16
52 Week High
$2.31
P/E
-0.32x
P/B
14.68x
P/S
13.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.26M
Earnings
-$20.58M
Gross Margin
100%
Operating Margin
-321.61%
Profit Margin
-391.3%
Debt to Equity
2.69
Operating Cash Flow
-$16M
Beta
0.69
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PSTV Overview
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PSTV's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PSTV
Ranked#175 of 488
Ranked#175 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $93.48 | A | |
| $14.66 | A |
Be the first to know about important PSTV news, forecast changes, insider trades & much more!
PSTV News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PSTV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PSTV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PSTV is poor value based on its book value relative to its share price (14.68x), compared to the US Biotechnology industry average (5x)
P/B vs Industry Valuation
PSTV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PSTV due diligence checks available for Premium users.
Valuation
PSTV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.32x
Industry
-9.18x
Market
41.56x
PSTV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
14.68x
Industry
5x
PSTV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PSTV's financial health
Profit margin
Revenue
$1.4M
Net Income
-$4.4M
Profit Margin
-316.6%
PSTV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PSTV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$18.7M
Liabilities
$13.6M
Debt to equity
2.69
PSTV's short-term assets ($17.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PSTV's short-term assets ($17.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PSTV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PSTV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
$1.3M
Financing
$12.3M
PSTV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PSTV vs Biotech Stocks
Plus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.